# US 2023/0056048 A1 · Method for enhancing expression of insulin like growth factor 1 receptor in umbilical cord mesenchymal stem cell and method for obtaining multipotent umbilical cord mesenchymal stem cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056048 A1
- Document ID: US20230056048A1
- Status: Published application
- Kind: A1
- Application number: 17/981,736
- Filed: 2022-11-07
- Published: 2023-02-23
- Earliest claimed: 2015-07-22
- Assignees: China Medical University
- Applicants: China Medical University
- Inventors: Woei-Cherng Shyu; Chen-Huan Lin; Wei Lee; Chia-Hung Hsieh; Chung-Y. Hsu; Chang-Hai Tsai
- Web page: https://patentgrep.com/patent/US20230056048A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12N 5/0665: {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}
- C12N 5/0668: {Mesenchymal stem cells from other natural sources}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- C12N 2500/84: from mammals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method for enhancing an expression of insulin like growth factor 1 receptor in an umbilical cord mesenchymal stem cell is provided. The method includes culturing the umbilical cord mesenchymal stem cell expressing insulin-like growth factor 1 receptor in a medium containing platelet-derived growth factor BB (PDGF-BB) to enhance the expression of insulin like growth factor 1 receptor in the umbilical cord mesenchymal stem cell.

## Claims

### Claim 1

A method for enhancing an expression of insulin like growth factor 1 receptor in an umbilical cord mesenchymal stem cell, the method comprising culturing the umbilical cord mesenchymal stem cell expressing insulin-like growth factor 1 receptor in a medium containing platelet-derived growth factor BB (PDGF-BB) at 2.5-50 ng/mL to enhance the expression of insulin like growth factor 1 receptor in the umbilical cord mesenchymal stem cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein a source of the PDGF-BB is human cord blood serum.

### Claim 3 (depends on 1)

The method of claim 1, wherein a concentration of the PDGF-BB in the medium is 5-50 ng/ml.

### Claim 4 (depends on 1)

The method of claim 1, wherein the medium further comprises a cytokine selected from a group consisting of epidermal growth factor (EGF), angiogenin (ANG), macrophage inflammatory protein-5 (MIP-1δ), regulated on activation, normal T-cell expressed and presumably secreted (RANTES), and a combination thereof.

### Claim 5

A method for obtaining a plurality of multipotent umbilical cord mesenchymal stem cells, the method comprising:
providing a human umbilical cord tissue;
cutting a Wharton’s jelly of the human umbilical cord tissue into pieces, then treating with collagenase type 1 and incubating for 14-18 hours;
culturing explants in DMEM containing human cord blood serum (hUCS) and antibiotics for 5-7 days to allow for migration of a plurality of cells from the explants; and
performing an isolation step, wherein the isolation step isolates the cells that express insulin-like growth factor 1 receptor (IGF1 R) and CD13, CD29, CD44, CD73, CD90, CD105, CD166, HLA-ABC, Oct-4, Sox-2, Nanog and SSEA-4 migrated from the explants to obtain the multipotent umbilical cord mesenchymal stem cells expressing IGF1 R and higher levels of Oct-4, Sox-2, Nanog and SSEA-4, which are representative markers for a multipotent capability.

### Claim 6 (depends on 5)

The method of claim 5, wherein the isolation step further comprises isolating the cells expressing interleukin 22 receptor alpha 1.